Author(s): Leach DR, Krummel MF, Allison JP, Leach DR, Krummel MF, Allison JP, Leach DR, Krummel MF, Allison JP, Leach DR, Krummel MF, Allison JP
Abstract Share this page
Abstract One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
This article was published in Science
and referenced in Immunotherapy: Open Access